About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- 120 people (mean age 19.9, range 4 to 66) with acquired hypothalamic obesity; 81 on setmelanotide, 39 on placebo
- Sample size
- 120
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Single phase 3 trial of 52 weeks. Serious adverse events were more frequent on setmelanotide. Mixed ages (4 to 66), so results may not apply equally to each group.
Cited in
Acquired hypothalamic obesity
Setmelanotide · Research finding
ModerateSerious adverse events in the hypothalamic obesity trial
Setmelanotide · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.